Cargando…

Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study

INTRODUCTION: Thyroid dysfunctions associated with SARS-CoV-2 acute infection have been extensively described since the beginning of COVID-19 pandemics. Conversely, few data are available on the occurrence of thyroid autoimmunity after COVID-19 resolution. We assessed the prevalence of autoimmune th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossini, Alessandro, Cassibba, Sara, Perticone, Francesca, Benatti, Simone Vasilij, Venturelli, Serena, Carioli, Greta, Ghirardi, Arianna, Rizzi, Marco, Barbui, Tiziano, Trevisan, Roberto, Ippolito, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031076/
https://www.ncbi.nlm.nih.gov/pubmed/36967795
http://dx.doi.org/10.3389/fendo.2023.1126683
_version_ 1784910523494563840
author Rossini, Alessandro
Cassibba, Sara
Perticone, Francesca
Benatti, Simone Vasilij
Venturelli, Serena
Carioli, Greta
Ghirardi, Arianna
Rizzi, Marco
Barbui, Tiziano
Trevisan, Roberto
Ippolito, Silvia
author_facet Rossini, Alessandro
Cassibba, Sara
Perticone, Francesca
Benatti, Simone Vasilij
Venturelli, Serena
Carioli, Greta
Ghirardi, Arianna
Rizzi, Marco
Barbui, Tiziano
Trevisan, Roberto
Ippolito, Silvia
author_sort Rossini, Alessandro
collection PubMed
description INTRODUCTION: Thyroid dysfunctions associated with SARS-CoV-2 acute infection have been extensively described since the beginning of COVID-19 pandemics. Conversely, few data are available on the occurrence of thyroid autoimmunity after COVID-19 resolution. We assessed the prevalence of autoimmune thyroid disease (ATD) and thyroid dysfunctions in COVID-19 survivors three months after hospital admission. DESIGN AND METHODS: Single-center, prospective, observational, cohort study performed at ASST Papa Giovanni XXIII Hospital, Bergamo, Italy. 599 COVID-19 survivors were prospectively evaluated for thyroid function and autoimmunity thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb). When a positive antibody concentration was detected, thyroid ultrasound was performed. Multiple logistic regression model was used to estimate the association between autoimmunity and demographic characteristics, respiratory support, and comorbidities. Autoimmunity results were compared to a cohort of 498 controls referred to our Institution for non-thyroid diseases before the pandemic onset. A sensitivity analysis comparing 330 COVID-19 patients with 330 age and sex-matched controls was performed. RESULTS: Univariate and multivariate analysis found that female sex was positively associated (OR 2.01, SE 0.48, p = 0.003), and type 2 diabetes (T2DM) was negatively associated (OR 0.36, SE 0.16, p = 0.025) with thyroid autoimmunity; hospitalization, ICU admission, respiratory support, or COVID-19 treatment were not associated with thyroid autoimmunity (p > 0.05). TPOAb prevalence was greater in COVID-19 survivors than in controls: 15.7% vs 7.7%, p = 0.002. Ultrasonographic features of thyroiditis were present in 94.9% of the evaluated patients with positive antibodies. TSH was within the normal range in 95% of patients. CONCLUSIONS: Autoimmune thyroid disease prevalence in COVID-19 survivors was doubled as compared to age and sex-matched controls, suggesting a role of SARS-CoV-2 in eliciting thyroid autoimmunity.
format Online
Article
Text
id pubmed-10031076
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100310762023-03-23 Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study Rossini, Alessandro Cassibba, Sara Perticone, Francesca Benatti, Simone Vasilij Venturelli, Serena Carioli, Greta Ghirardi, Arianna Rizzi, Marco Barbui, Tiziano Trevisan, Roberto Ippolito, Silvia Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Thyroid dysfunctions associated with SARS-CoV-2 acute infection have been extensively described since the beginning of COVID-19 pandemics. Conversely, few data are available on the occurrence of thyroid autoimmunity after COVID-19 resolution. We assessed the prevalence of autoimmune thyroid disease (ATD) and thyroid dysfunctions in COVID-19 survivors three months after hospital admission. DESIGN AND METHODS: Single-center, prospective, observational, cohort study performed at ASST Papa Giovanni XXIII Hospital, Bergamo, Italy. 599 COVID-19 survivors were prospectively evaluated for thyroid function and autoimmunity thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb). When a positive antibody concentration was detected, thyroid ultrasound was performed. Multiple logistic regression model was used to estimate the association between autoimmunity and demographic characteristics, respiratory support, and comorbidities. Autoimmunity results were compared to a cohort of 498 controls referred to our Institution for non-thyroid diseases before the pandemic onset. A sensitivity analysis comparing 330 COVID-19 patients with 330 age and sex-matched controls was performed. RESULTS: Univariate and multivariate analysis found that female sex was positively associated (OR 2.01, SE 0.48, p = 0.003), and type 2 diabetes (T2DM) was negatively associated (OR 0.36, SE 0.16, p = 0.025) with thyroid autoimmunity; hospitalization, ICU admission, respiratory support, or COVID-19 treatment were not associated with thyroid autoimmunity (p > 0.05). TPOAb prevalence was greater in COVID-19 survivors than in controls: 15.7% vs 7.7%, p = 0.002. Ultrasonographic features of thyroiditis were present in 94.9% of the evaluated patients with positive antibodies. TSH was within the normal range in 95% of patients. CONCLUSIONS: Autoimmune thyroid disease prevalence in COVID-19 survivors was doubled as compared to age and sex-matched controls, suggesting a role of SARS-CoV-2 in eliciting thyroid autoimmunity. Frontiers Media S.A. 2023-03-08 /pmc/articles/PMC10031076/ /pubmed/36967795 http://dx.doi.org/10.3389/fendo.2023.1126683 Text en Copyright © 2023 Rossini, Cassibba, Perticone, Benatti, Venturelli, Carioli, Ghirardi, Rizzi, Barbui, Trevisan and Ippolito https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Rossini, Alessandro
Cassibba, Sara
Perticone, Francesca
Benatti, Simone Vasilij
Venturelli, Serena
Carioli, Greta
Ghirardi, Arianna
Rizzi, Marco
Barbui, Tiziano
Trevisan, Roberto
Ippolito, Silvia
Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
title Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
title_full Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
title_fullStr Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
title_full_unstemmed Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
title_short Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
title_sort increased prevalence of autoimmune thyroid disease after covid-19: a single-center, prospective study
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031076/
https://www.ncbi.nlm.nih.gov/pubmed/36967795
http://dx.doi.org/10.3389/fendo.2023.1126683
work_keys_str_mv AT rossinialessandro increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT cassibbasara increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT perticonefrancesca increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT benattisimonevasilij increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT venturelliserena increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT carioligreta increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT ghirardiarianna increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT rizzimarco increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT barbuitiziano increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT trevisanroberto increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy
AT ippolitosilvia increasedprevalenceofautoimmunethyroiddiseaseaftercovid19asinglecenterprospectivestudy